Clinical Trials · NCT04462900

Evaluate the Safety of Linaclotide in IBS-C Patients in China

Name: Evaluate the Safety of Linaclotide in IBS-C Patients in China
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/ALinaclotide

Phase: N/A
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 3,028
Start date: Sep 2020
Locations: 29 sites, China
Primary endpoint: Demonstrate the safety of linaclotide therapy

View Linaclotide compound reference